June 5, 2013 Welcome to the Sixth Massachusetts Life Sciences Innovation Day! Once again, we bring together major organizations throughout the state to create a high-energy, hands- on event which includes scientific leaders and business experts to mingle with innovators, post-docs, professors, entrepreneurs, innovators, and venture capitalists. This is the biggest day for life sciences startups and innovation in the Commonwealth of Massachusetts. This year’s theme is “Business as Usual or Brave New World?” Can we learn valuable lessons from life sciences start-up companies that have already been formed and funded? Or are life sciences entrepre- neurs entering a “Brave New World” where their path to success is going to be completely different? Our speakers and panelists will consider the current status of life sciences and what changes we should ex- pect in the future. How will these changes impact basic research, technology commercialization, invest- ment in new companies, and scientists’ careers? Our speakers and panelists have years of experience and represent a wide range of technologies and inventions. They are presidents, CEOs, partners and consultants of leading companies and institutions throughout the area. We hope you find their discus- sions informative and imaginative. The Poster Competition includes some of the greatest and newest ideas that could impact medicine in the future. Remember to invest your “MALSI dollars” in your favorite posters – it could help the inventors raise their first round of investment! Winners will be announced during our ever popular evening recep- tion attended by many CEOs who have taken on the judging of the posters. Don’t miss the opportunity to speak with them and discuss your projects. We are particularly grateful to our Planning Committee for their help, support and entrepreneurial spirit in organizing this event. We would also like to thank all of our sponsors, particularly the Massachusetts Life Sciences Center, our lead sponsor for this event. All of our sponsors are as committed as we are to supporting the creation of new companies and we are grateful to them all. We hope you enjoy our flagship event of life sciences in Massachusetts, jointly and actively put together by all the major organizations that are involved in starting and supporting the life sciences start-up eco- system in the Commonwealth. . . Dr. Abigail A. Barrow Chair MALSI Director, Massachusetts Technolgy Transfer Center
Transcript
June 5, 2013
Welcome to the Sixth Massachusetts Life Sciences Innovation Day!
Once again, we bring together major organizations throughout the state to create a high-energy, hands-on event which includes scientific leaders and business experts to mingle with innovators, post-docs, professors, entrepreneurs, innovators, and venture capitalists. This is the biggest day for life sciences startups and innovation in the Commonwealth of Massachusetts.
This year’s theme is “Business as Usual or Brave New World?” Can we learn valuable lessons from life sciences start-up companies that have already been formed and funded? Or are life sciences entrepre-neurs entering a “Brave New World” where their path to success is going to be completely different? Our speakers and panelists will consider the current status of life sciences and what changes we should ex-pect in the future. How will these changes impact basic research, technology commercialization, invest-ment in new companies, and scientists’ careers? Our speakers and panelists have years of experience and represent a wide range of technologies and inventions. They are presidents, CEOs, partners and consultants of leading companies and institutions throughout the area. We hope you find their discus-sions informative and imaginative.
The Poster Competition includes some of the greatest and newest ideas that could impact medicine in the future. Remember to invest your “MALSI dollars” in your favorite posters – it could help the inventors raise their first round of investment! Winners will be announced during our ever popular evening recep-tion attended by many CEOs who have taken on the judging of the posters. Don’t miss the opportunity to speak with them and discuss your projects.
We are particularly grateful to our Planning Committee for their help, support and entrepreneurial spirit in organizing this event. We would also like to thank all of our sponsors, particularly the Massachusetts Life Sciences Center, our lead sponsor for this event. All of our sponsors are as committed as we are to supporting the creation of new companies and we are grateful to them all.
We hope you enjoy our flagship event of life sciences in Massachusetts, jointly and actively put together by all the major organizations that are involved in starting and supporting the life sciences start-up eco-system in the Commonwealth.
.
.
Dr. Abigail A. BarrowChair MALSIDirector, Massachusetts Technolgy Transfer Center
6th AnnualMassachusetts Life Sciences Innovation Day
ii
Table of ContentsFloor Plan – Harvard Club of Boston ................................................................................................v
MALSI Day Planning Committee ................................................................................................... 29
Sponsors, Affiliates & Organizers ................................................................................................... 31Gold Sponsors.................................................................................................................................................................32Silver Sponsors ...............................................................................................................................................................33Conference Supporters ...............................................................................................................................................35Organizers ........................................................................................................................................................................36In association with .......................................................................................................................................................39
Poster Presenters ................................................................................................................................. 41Beth Israel Deaconess Medical Center ...................................................................................................................43Beth Israel Deaconess Medical Center ...................................................................................................................43Boston University ..........................................................................................................................................................43Boston University ..........................................................................................................................................................43Broad Institute of MIT and Harvard .........................................................................................................................43CuriRx, Inc .........................................................................................................................................................................44Flow Forward Medical, LLC ........................................................................................................................................44Harvard Medical School ..............................................................................................................................................44Harvard Medical School ..............................................................................................................................................44Harvard Medical School ..............................................................................................................................................44Harvard Medical School ..............................................................................................................................................45Harvard University ........................................................................................................................................................45Harvard University & Brigham & Women’s Hospital ..........................................................................................45LambdaVision, Inc .........................................................................................................................................................45Massachusetts Institute of Technology .................................................................................................................45Massachusetts Institute of Technology .................................................................................................................46Northeastern University ..............................................................................................................................................46Roundhouse Therapeutics .........................................................................................................................................46The Forsyth Institute.....................................................................................................................................................46TriBiotica LLC ...................................................................................................................................................................46Tufts University ...............................................................................................................................................................46Tufts University School of Medicine .......................................................................................................................47Tufts University School of Medicine .......................................................................................................................47Tufts University ...............................................................................................................................................................47Tufts University ...............................................................................................................................................................47Tufts University ...............................................................................................................................................................47
6th AnnualMassachusetts Life Sciences Innovation Day
iv
Tufts University ...............................................................................................................................................................48University of Massachusetts Dartmouth ...............................................................................................................48University of Massachusetts Lowell ........................................................................................................................48University of Massachusetts Medical School.......................................................................................................48Wyss Institute & Harvard University ........................................................................................................................48
Innovators’ Marketplace Exhibitors ............................................................................................... 49Life Science Products and Services ........................................................................................................................49Entrepreneurship Support .........................................................................................................................................49Funding .............................................................................................................................................................................50Professional Services ....................................................................................................................................................50
Floor Plan – Harvard Club of Boston
TIME SESSION
Foyer Harvard Hall
8:00 AM Registration & Breakfast
Harvard Hall
9:00 AM Welcome by Conference Chair Abigail Barrow, Director, Massachusetts Technology Transfer Center
9:15 AM Opening Panel: Getting to First Base – CEOs Who Have Recently Raised MoneyPanelists:
Bill Edelman, Chairman at Large Michael Fahey, President and Cloud Architect, Infobionic Inc.
Carolyn Green, President and Director, Atreaon Inc.Albine Martin, COO, Precision Biologics, Inc
Moderator: Carl Berke, Partner, Partners HealthCare Innovation Fund
10:00AM 7 Habits of Extraordinary Successful Life Sciences CompanyAbbie Celniker, CEO, Eleven Biotherapeutics
Harvard Foyer and Commonwealth Lounge on the 1st Floor
NovartisAuro Nair, General Manager, Scientific Research
Services, Jackson Laboratory Moderator: Mark Namchuk, Senior VP of
Research for North America, Vertex
Selling Your Idea / Pitching Your Company Pitches by:
Roger Frechette, President & CEO, Frontiera Therapeutics
Frederick Jones, Founder, Roundhouse TherapeuticsRobert Thompson, President & CEO, Amorphex
TherapeuticsPanelists:
Joshua Phillips, Managing Partner, Catalyst Health Ventures
Kiran Reddy, Associate Partner, Third Rock VenturesModerator: Linda Plano, Founder, Plano & Simple
Harvard Hall - Lunch
12:15 PM Panel 1: The Future of the Academic Industrial ComplexPanelists:
John Brooks, President & CEO, Joslin Diabetes Center Deborah Dunsire, Former President & CEO, Millennium: The Takeda Oncology Company
Sanjeev Munshi, Director, Business Development, Worldwide Licensing & Acquisitions, Merck Michael Malone, Vice Chancellor for Research & Engagement, University of Massachusetts AmherstModerator: Douglas Banks, Associate VP for Economic Development,University of Massachusetts
Panel 2: Are Virtual Companies Faster, Better and Cheaper?Panelists:
Irene AbramsDirector, Research Ventures & Licensing, Partners Healthcare
Irene leads a team responsible for commercialization of inventions in the areas of biology and medicine arising from research at Massachusetts General Hospital. Prior to joining Partners, Irene was the Associate Provost for Innovation at Brandeis University and founded the Brandeis Virtual Incubator, a proof-of-concept center with the mission of fostering entrepreneurship among students and faculty in the sciences by provid-ing mentorship, education, and small seed grants to help them move inventions from the lab to the market-place. Before joining Brandeis in 2006, Irene was a Senior Technology Licensing Officer at M.I.T., where she focused on licensing biotech inventions for M.I.T., the Whitehead Institute and the Broad Institute. Irene did her undergraduate work at the University of Pennsylvania and her graduate work at the Johns Hopkins Uni-versity and at M.I.T. Irene is the past President of the Massachusetts Association of Technology Transfer Of-fices, the founder of T3, a networking organization for technology licensing offices from small New England research institutions, and an Associate Vice President of the Association of University Technology Managers.
Omar AmiranaManaging Director, Life Sciences, Allied Minds
Omar is the Managing Director of Life Sciences for Allied Minds. Omar previously served as a Partner at Ox-ford Biosciences Partners, a Boston-based venture capital firm with ~$1B under management. He sourced and led the Series A investment in nFocus Neuromedical which commercialized a catheter-based aneu-rysm therapy and was recently sold to Covidien for ~$100M. He has served on the boards of Flowmedica (renal therapy; sold to AngioDynamics), SmartPill (GI capsule technology; sold to Given Imaging), Coherex (catheter closure of LAA and PFO), Mitralign (percutaneous heart valve repair), and Cambridge Endoscopic Devices (articulating laparoscopic surgical tools). He was the co-founder of Cardima (AF ablation; IPO) and Resolution Medical (cardiac mapping) based in Silicon Valley. He was also the VP of Marketing of Medica-Logic/Medscape, (EMR/HCIT), and served as VP of Business Development at St. Jude Medical (STJ, $5.2B in revenue). He has developed and launched products worldwide. He is currently on the board of Cardiofo-cus (AF catheter ablation) as well as the Oversight Committee for the Coulter Translational Research Part-nership at Columbia University. As a co-founder of Propel Careers, he is passionate about helping aspiring entrepreneurs in life sciences. Omar earned a BS in Mechanical Engineering from Tufts University and an MD from Eastern Virginia Medical School.
Richard AndersFounder and Executive Director, MA Medical Angels (MA2)
Richard Anders is a seasoned entrepreneur who has had careers in computers, publishing and consulting, and has a strong personal focus on life sciences and life-science investing. He founded the legal software publishing company Jurisoft, which he sold to Lexis/Nexis, published newspapers including Boston Digital Industry and New York Digital Industry and was a founding trustee of the Massachusetts Interactive Media
6th AnnualMassachusetts Life Sciences Innovation Day
12 Biographies
Council. Richard is a trustee of the Boston Museum of Science, a former trustee of the Boston Biomedical Research Institute and an overseer of the Gardner Museum. He served for many years as a member of the Institutional Review Board at the Dana Farber Cancer Center, reviewing clinical trials for the hospital. He founded the angel group Launchpad and founded and currently runs MA Medical Angels (MA2), one of the country’s leading angel groups focused exclusively on life sciences. He founded the nationally renowned Science on Screen event at the Coolidge Corner Cinema, which has received $750,000 in grants from the Sloan Foundation to extend nationally. He is a board observer at Avaxia Biologics and Sialix, and served on the board of Quosa, Inc. which was acquired by Elsevier Publishing, and Bliss Healthcare. Richard teaches medical device entrepreneurship at the Harvard/MIT HST program. Richard is a graduate Summa Cum Laude in Mathematics from Harvard and holds a JD from Harvard Law School.
Robert AndersonPartner, Lathrop & Gage LLP
Bob is a Partner in the nationwide life sciences law firm of Lathrop & Gage LLP. He brings more than 24 years of experience in the field of biotechnology to his clients. His practice is focused on licensing and acquiring strategic intellectual property rights, and researching, developing and commercializing novel therapeutics and diagnostics. His experience includes bringing innovative biotechnology from concept to commercializa-tion, including most notably providing two decades of support for HUMIRA® the world’s highest selling phar-maceutical. Bob has extensive experience in global transactional law including technology transfer, licens-ing, collaborative research and clinical trial agreements as well as mergers and acquisitions. International experience includes both Europe and Japan. His team of professionals provided legal support that helped Abbott earn the award of Most Admired Corporate Dealmaker for four consecutive years and Abbott was also named the Best Legal Department by Corporate Counsel. Prior to joining Lathrop & Gage, he was respon-sible for providing legal support for the licensing and developing of global pharmaceutical products and clini-cal candidates for Abbott Laboratories, a Fortune 100 global healthcare company (Abbott is now “AbbVie”). Bob was a key player in acquiring, protecting and enabling Abbott Laboratories’ pharmaceutical products pipeline, particularly in the areas of biologics research and development, manufacture and commercializa-tion. He formerly served as General Counsel for BASF Bioresearch Corporation (BASF is an international Fortune 100 corporation). Bob was a founding member of BASF Bioreasearch Corporation’s (BBC) manage-ment team, which built a world-class research, development and biologics manufacturing organization from 10 employees up to approximately 800 scientists, clinicians, engineers, and professional staff. He was also a key member of the BASF’s legal team that finalized the $6.9 Billion acquisition of Knoll AG (BASF AG’s worldwide pharmaceutical company) by Abbott.
Doug Banks is Associate Vice President for Economic Development for the five-campus University of Mas-sachusetts system, serving on the staff of President Robert L. Caret. In this position, Doug is responsible for promoting and developing strategic partnerships amoung the campuses and between state and federal government, business and industry, and other public and private institutions of higher education. Focus areas include clean energy, life sciences, defense technologies and Cybersecurity, and entrepreneurship. In addi-tion, he manages the President’s Science & Technology Initiatives Fund, an inter-campus grant program to strengthen the university’s R&D base and strengthen industry relationships. He co-chairs a national working
June 5, 2013Harvard Club of Boston
Biographies 13
group launching the Innovation & Economic Prosperity Awards program for the Commission on Innovation, Competitiveness, and Economic Prosperity of the Association for Public and Land-grant Universities. Doug joined his alma mater following a career in technology and business journalism, most recently serving as publisher and editor of Mass High Tech.
Abigail BarrowFounding Director, Massachusetts Technology Transfer Center and Conference Co-Chair
Dr. Abigail Barrow is the Founding Director of the Massachusetts Technology Transfer Center (MTTC) where she is responsible for the overall management of the MTTC and the development of its programs. The MTTC supports the creation of new companies based on research being undertaken at the universities, research institutions and hospitals in the Commonwealth. Prior to joining the MTTC, Dr. Barrow served as managing director of William J. von Liebig Center at the University of California San Diego (UCSD). The von Liebig Center was created in 2001 to support the commercialization of research being performed in the UCSD Ja-cobs School of Engineering.
Dr. Barrow worked in a variety of roles at UCSD CONNECT from 1990 to 2001. At CONNECT, she developed and expanded many of its programs to support early-stage company formation and technology commercial-ization. The CONNECT program is internationally recognized and has been successfully replicated in many other regions around the world.
Dr. Barrow is on the board of the National Collegiate Inventors and Innovators Alliance (NCIIA) and on the scientific advisory board of Norway’s Simula Research Laboratory. Dr. Barrow received her Ph.D. from the Science Studies Unit and a B.Sc. in Mechanical Engineering from the University of Edinburgh.
Jonathan BehrVice President of New Ventures, Enlight Biosciences
Jon focuses on new business creation, operations, and business development activities at Enlight. Previ-ously he was a Principal with PureTech Ventures where he was a member of the founding teams of Enlight, Endra, Vedanta, Mandara, and Tal Medical. Jon earned his Ph.D. in Biological Engineering at MIT, as a Howard Huges pre-doctoral fellow, and his BS in Biological Engineering from Rice University with Honors, summa cum laude, where he was Phi Beta Kappa co-valedictorian. He was awarded the inaugural Rice Bio-engineering Outstanding Undergraduate Alumnus Award for his post-baccalaureate achievements.
Carl BerkePartner, Partners HealthCare Innovation Fund
Carl is a Partner at the Partners HealthCare Innovation Fund in Boston, investing in new biomedical tech-nologies emerging from Massachusetts General Hospital and Brigham & Women’s Hospital. His career has spanned over 25 years in the practice and management of innovation to bring new technologies from lab to market. As a bench scientist and R&D director, he worked at Polaroid Corporation and Hygeia Sciences in the development of photographic and clinical products for both consumer and professional markets - he is an
6th AnnualMassachusetts Life Sciences Innovation Day
14 Biographies
inventor on 6 US patents. He served as a Partner at Integral/Analysis Group, a consulting firm, focusing on the management of innovation and growth strategy. He has been an active private equity investor as a mem-ber of Angel Healthcare Investors LLC and is a founding director of Mass Medical Angels. He has served on the boards of Quosa (research literature management software), Kasalis (robotics), Annovation (anesthetic agents), Combinent (women’s health), Sebacia (acne treatment), InfoBionic (cardiac monitoring) and the Sudanese Education Fund (philanthropy). Carl holds an AB degree from Cornell University and received his Ph.D. in Organic Chemistry from the University of California at Berkeley. He also holds an appointment as Lecturer in the Biomedical Enterprise Program in the Harvard-MIT Division of Health Sciences and Technol-ogy.
Nancy BriefsCEO, InfoBionic
Ms. Briefs’ background includes 30+ years in the medical device industry. She is a serial entrepreneur and has been an integral team member responsible for successfully developing and commercializing innovative paradigm shifting technologies with five (5) prior med-tech startups. Having raised over $200M in venture capital and four successful liquidity events (including an IPO with Goldman Sachs) she has proven the ability to lead teams from concept thru commercialization and value creation. She was awarded: with the Ernst & Young (EOY) New England Entrepreneur of the Year Award for Emerging Companies in 2003; received the “Spirit Award” in 2009 from NH Biotech Council and in 2010 was honored with a “Leadership & Inspiration: Award from WEST (Women Entrepreneurs in Science and Technology). She currently serves on the Boards of: MDMA (Medical Device and Manufacturers Association), CardiAQ Valve Technologies, Apama Medical and InfoBionic. An entrepreneur inventor she is listed on seven issued and two pending US patents. Nancy has an MBA in Marketing and Finance from Golden Gate University and a BA and BSB from Emporia Uni-versity. A notable and inspiring public speaker, Ms. Briefs has spoken at the MIT Enterprise Forum, Harvard Medical School, Tuck School at Dartmouth College, NH Women’s Leadership Conference, Smith College, WEST, MassMEDIC, MIT Sloan School, Venture One, MDMA, MedTech Insight, OneMedForum and other numerous industry events.
John BrooksPresident and CEO, Joslin Diabetes Center
John L. Brooks III is President and Chief Executive Officer of Joslin Diabetes Center. A well-known life sci-ences executive, Brooks assumed the President and Chief Executive Officer responsibilities in March 2011, having previously served as Chairman of the Joslin Board of Trustees.
Mr. Brooks co-founded three life sciences companies including Insulet, which offers an insulin-pump system for people with type 1 diabetes. He has been principal of Healthcare Capital Consulting LLC, which advises early-stage life sciences companies, and a founder of Prism VentureWorks, which raised more than $1.25 billion in capital. Brooks has been Chief Executive Officer of Reflectance Medical, which offers technology for non-invasive monitoring of critically ill patients. He was also general manager at Pfizer/Valleylab, where he was responsible for Pfizer’s Hospital Products Group’s minimally invasive surgery and new medical tech-nologies business. As President/General Manager at Pfizer/Strato, he led the growth of a rapidly evolving vascular access medical device business. A native of Massachusetts, he holds an M.S. in Business and a B.B.A. cum laude from the University of Massachusetts at Amherst.
June 5, 2013Harvard Club of Boston
Biographies 15
Charles CameronFounder/Managing Director, Hub Angel Investment Group, LLC
Charlie has over 20 years of management consulting, marketing and investing experience in more than 30 countries. His experience ranges from working on strategy with Fortune 500 companies to mentoring emerg-ing technology companies to venture investing. He works with entrepreneurs, investors and family offices in Europe, the US and Canada. In addition, he is SVP of Business Development at Cooley LLP, a national law firm with a broad, technology-oriented client base. He currently sits on the Advisory Board of The Capital Network, helping entrepreneurs to learn how to fund their startup. During the past decade Charlie has built a global network of entrepreneurs, VCs, angel groups, and service providers. Charlie has an MBA from MIT, an MPH from Harvard University, and a BA, Economics-honors, Phi Beta Kappa, from the University of Mas-sachusetts.
Lauren CelanoCo-founder and CEO, Propel Careers
Lauren Celano is the co-founder and CEO of Propel Careers, a life science search and career development firm focused on connecting talented individuals with entrepreneurial life sciences companies. Propel works with current leaders and actively cultivates future leaders through full time placement, internships, mentor-ing, career coaching, and networking. Propel Careers is engaged across all areas of life sciences, includ-ing therapeutics, medical devices, healthcare IT, diagnostics, consulting, venture capital, and investment banking. Prior to Propel Careers, Lauren was a senior account manager for SNBL USA where she worked with emerging biotech companies in Europe, Asia, and the US to help characterize and advance their drug molecules. Prior to SNBL USA, she held business development positions with Aptuit and Quintiles, where she focused on IND enabling studies to advance therapeutics from discovery into the clinic. Earlier in her career, Lauren held positions as a marketing manager and account manager at Absorption Systems, where she was responsible for managing life sciences companies in the northeastern United States. She has a B.S. in Biochemistry and Molecular Biology from Gettyburg College and an MBA with a focus in the health sector and entrepreneurship from Boston University. Lauren is on the membership committee of the Boston Chapter of the Healthcare Businesswomen’s Association and she also serves on the programming committee of the Capital Network.
Abbie CelnikerCEO, Eleven Biotherapeutics
Dr. Celniker brings more than 20 years of proven expertise in leading protein therapeutic discovery and development companies and programs to Eleven Biotherapeutics. Prior to joining Eleven, Abbie was CEO of Taligen Therapeutics, a biotechnology company focused on complement system regulation, which was acquired by Alexion Pharmaceuticals in January 2011. Prior to Taligen, Dr. Celniker was global head of bio-logicals at Novartis, where she oversaw the biologics division, forged strategic alliances, and led internal discovery and development to build the pipeline. Prior to Novartis, Dr. Celniker spent more than six years at Millennium Pharmaceuticals as senior vice president, R&D strategy and operations and head of biotherapeu-tics and pharmaceutical sciences. Previously, she held senior research and development leadership roles with Wyeth BioPharma (Genetics Institute) and Genentech. Dr. Celniker holds a Ph.D. in Molecular Biology from the University of Arizona and a B.A. in Biology from the University of California, San Diego.
6th AnnualMassachusetts Life Sciences Innovation Day
16 Biographies
David CohenDirector of Hepatology, Brigham and Women’s Hospital, BostonDirector, Harvard-MIT Division of Health Sciences and Technology, Boston
Dr. Cohen received his medical degree from Harvard Medical School. He also earned a PhD in physiol-ogy and biophysics at Harvard University. He completed his residency and served as a research fellow in internal medicine at Harvard Medical School and Brigham and Women’s Hospital in Boston. Subsequently, Dr. Cohen completed a clinical fellowship and a research fellowship in gastroenterology at Harvard Medical School and Brigham and Women’s Hospital. In 1995, Dr. Cohen was appointed as Instructor in Medicine at Harvard Medical School and Assistant Professor in 1996. In 1997, he moved to the Albert Einstein College of Medicine, where he held joint apointments in the Departments of Medicine and Biochemistry as a member of the Marion Bessin Liver Research Center. Dr. Cohen returned to Harvard Medical School and Brigham and Women’s Hospital in 2004. Dr. Cohen is currently the Director of Hepatology at Brigham and Women’s Hospital, and Director of the Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology. Dr. Cohen is a Master of the Irving M. London Society of HST at Harvard Medical School. He is a faculty member of the graduate program in Biological and Biomedical Sciences, and an affiliate of the Department of Biological Chemistry and Molecular Pharmacology, at Harvard Medical School. Dr. Cohen’s current research interests include the role of START domain proteins in lipid and glucose metabolism, as well as the impact of obesity on hepatic cholesterol metabolism. Dr. Cohen has won a number of awards; has published numerous articles and is the author of multiple book chapters.
Cliff CulverFounder & CEO, OnDeckBiotech
Cliff Culver is the founder and CEO of OnDeckBiotech, an online platform for biotech companies to stream-line internal coordination of their vendor relationship management. OnDeck simplifies paperwork, acceler-ates sourcing, and allows biotech executives to return their focus to driving R&D. The platform covers CROs, CMOs, labs, regulatory consultants from discovery through commercialization and is used by service provid-ers to increase awareness for their capabilities and expertise. OnDeck recently launched the MassBio Gate-way in partnership with MassBio to highlight the many world-class CROs and CMOs local to New England. Prior to founding OnDeckBiotech, Cliff worked in corporate strategy and new ventures for the Advisory Board Company (NASDAQ: ABCO) where he co-authored the firm’s five-year growth strategy, evaluated health IT acquisitions and investments; and led the market research, initial development, and early sales of SaaS products targeting health care providers.
Prem DasChief Research Business Development Officer, Dana-Farber Cancer Institute (DFCI)
Prem Das is the Chief Research Business Development Officer at Dana-Farber Cancer Institute (DFCI) and heads DFCI’s Office of Research and Technology Ventures. He is also responsible for growing DFCI’s research business development, working with DFCI faculty and Integrative Research Centers to enhance relationships with the corporate sector, generating sponsored research agreements, and commercializing DFCI discoveries. Prem’s background includes managing academic technology transfer offices, biotech-
June 5, 2013Harvard Club of Boston
Biographies 17
nology business development, and basic research. Most recently, Prem was involved in creating start-up companies and consulting for biotechnology companies and the NCI. Prior to this, he served as Senior Vice President for Technology Alliances at Praecis Pharmaceuticals, where his business development efforts led to the acquisition of the company by Glaxo-Smith Kline. Prem also has directed the Office of Technology Licensing at Harvard Medical School and the Office of Industrial Affairs at Memorial Sloan-Kettering Cancer Center. In addition, he has worked at Cadus Pharmaceuticals and co-founded Heartland BioTechnologies. During his academic research career, Prem published in various areas of biology. He received his MSc in chemistry from IIT/Kanpur in India and his PhD in biological chemistry from MIT.
Deborah DunsireFormer President & CEO, Millennium: The Takeda Oncology Company
Deborah Dunsire MD was the President and Chief Executive Officer of Millennium Pharmaceuticals Inc. from July 2005 to May of 2013. In 2008 Millennium was acquired by Takeda Pharmaceuticals of Japan, becom-ing the global oncology center of excellence for Takeda under her leadership. Dr. Dunsire joined Millennium from her role as Senior Vice President and North American region head of the Oncology Business Unit of Novartis in July 2005. Prior to her move to the U.S. in 1994 – Dr. Dunsire worked in the global headquarters of Sandoz in Switzerland managing launch and growth of global products in the field of immunology and dermatology. She joined Sandoz in South Africa in 1988 as a clinical researcher and expanded her resume to include portfolio and specialty market management.
Dr. Dunsire is a member of the Board of Directors of Takeda Pharmaceuticals in Japan and of Allergan Inc. in Irvine, California. Her not for profit board memberships include CancerCare Inc; the G&P Foundation for Cancer Research and the Boston Museum of Science where she chairs the Investment Review Board. She served as a Director of the Biotechnology Industry Organization where she co-chaired the Regulatory and Environment committee and served as a member of the Executive Committee from 2008 to 2013. She served as a Director of Pharmaceutical Research and Manufacturers of America (PhRMA) from 2005-2008 and as a Director of California Healthcare Institute from 2002 - 2005. Dr. Dunsire was the 2001 recipient of the American Cancer Society Excalibur Award and the 2000 recipient of the Health Care Business Women’s Association Rising Star Award, the 2009 Health Care Business Women’s Association Woman of the Year Award, and 2011 Massachusetts Biotechnology Organization’s Innovative Leadership Award. She received a PhD Honoris Causa from Worcester Polytechnic Institute in 2007. Dr. Dunsire graduated as a physician from the University of Witwatersrand in Johannesburg, South Africa and practiced medicine as a General Practitioner before moving into industry.
Bill EdelmanChairman at Large
Bill Edelman, is a medical device industry executive with over 34 years experience and currently serves as Chairman of the Board for NewVert, Ltd., (spinal implants), Highland Instruments, Inc., (neurostimulation), Chairman of the Board for Paragonix Technologies, Inc., (organ transport systems), and Leviticus Cardio, Ltd., (cardiac assist power systems). Co-Chairman for ETView, Ltd., (TASE: ETVW) (airway management), Chairman of the Board for Medivalve, Ltd., (percutaneous aortic valve placement) and Cardioflow, Ltd., (em-bolic protection). Mr. Edelman also serves as a Board Member for MindChild Medical, Inc., (non-invasive fetal monitoring). Mr. Edelman is an Advisor on the Healthcare Board, for Northeast Securities, Inc., and serves as a member of the Advisory Council for the Department of Biomedical Engineering at Rensselaer Polytechnic
6th AnnualMassachusetts Life Sciences Innovation Day
18 Biographies
Insitute. Mr. Edelman recently served as a member of the Screening Committee, Medical Devices for Mass Medical Angels, Chairman of the Board for PolyTouch, Ltd., acquired by Covidien in 2011 (general surgical instrumentation) and Stimatix GI, Ltd., (ostomy products). Previously, Mr. Edelman served as President & Chief Executive Officer, TYRX, Inc., a commercial stage venture backed medical device company focused in drug/device implant products for general surgery, electrophysiology and cosmetic surgery. Prior to TYRX, Mr. Edelman held executive level positions at MicroSense International, LLC (bio-sensing), FibraSonics, Inc. (ultrasonic surgical products), NeuroMod, Inc. (neuro-stimulation technologies), St. Jude Medical, Inc. (NYSE: STJ), Pfizer, Inc. (NYSE: PFE), and Baxter International, Inc. (NYSE: BAX). Mr. Edelman graduated with a degree in Biomedical Engineering from Rensselaer Polytechnic Institute. He has been 15 U.S. patents and is an applicant on 5 additional pending patent applications.
Michael FaheyPresident and Cloud Architect, InfoBionic, Inc.
Michael Fahey is the President and Co-Founder of InfoBionic, a medical device company developing a cloud based remote physiologic monitoring system based at Mass Medical Device Development Center (M2D2) at UMass Lowell. He is an experienced technology executive with a BSEE and Math Minor from the Univer-sity of Lowell (1988) and an MBA in High Technology (member Beta Gamma Sigma Honor Society) from Northeastern University (2005). Prior to founding InfoBionic in March 2011, Michael was the Senior Director of File and Cloud Services for Hitachi Data Systems (via acquisition of Archivas) and was responsible for unstructured information and cloud storage. Previous to that he worked in Product Management, Solution Development, and Sales roles for EMC, Network Appliance, and several startups including Archivas, Acopia, WebDialogs, and Sherpa. Michael has significant background with cloud providers in vertical markets includ-ing security, healthcare, finance, government, and retail. He serves on the Advisory Board for Cleversafe and has presented at numerous industry forums on topics including object storage, data forensics, M2M, cloud, and healthcare. Michael holds one issued and two pending patent applications. Michael served in the United States Marine Corps and he also served as a Peace Corps Volunteer in Liberia.
Jose-Maria FernandezLaboratory for Financial Engineering, MIT Sloan
Jose-Maria Fernandez’s recent work has focused on the creation of new models and financing solutions to accelerate the development of new cures for cancer and other disease. His more recent work has been published in Nature Biotechnology under the title “Commercializing biomedical through securitization tech-niques”. Prior to MIT he worked in debt capital markets for over ten years. Between 2005 and 2008 he was a Managing Director for Credit Agricole CIB in London where he ran the Debt Capital Markets Global Origi-nation department for Sovereigns, Supranational and Development Agencies. Under his leadership, Credit Agricole’s IFR euro league table ranking in this market segment successfully shifted to first in May of 2008, up from 14th at the end of 2005. Previously, since late 1997 Jose-Maria worked in the Spanish Ministry of Finance. In November 2002 he was appointed Head of the Public Debt department (Treasury Department, Ministry of Finance, Madrid). In that position he was responsible for the capital market operations of the Kingdom of Spain, funding annually over $100b through the issuance and management of a multicurrency portfolio of debt securities. In this position he was also in charge for the management of the Kingdom’s $400b liability portfolio. Jose-Maria holds a MBA degree from MIT Sloan (Sloan Fellows Program in Innovation and Global Leadership), a Masters in Finance degree from the London Business School and Bachelor’s Degree in Economics and Business from CUNEF in Madrid. He was appointed State Economist and Trade Expert of the Spanish General Government in 1997.
June 5, 2013Harvard Club of Boston
Biographies 19
Roger FrechettePresident & CEO, Frontiera Therapeutics
Roger Frechette, Ph.D. is CEO and Co-Founder of Frontiera Therapeutics, a startup emerging from Tufts Medical Center to develop a novel treatment for Acute Respiratory Distress Syndrome (ARDS). He is also a partner and co-founder of New England PharmAssociates (NEPA), which provides on-demand executive and advisory services to life sciences enterprises. Dr. Frechette volunteers as Entrepreneur-in-Residence, Advisor and Leadership Team Member with North Shore InnoVentures, a Beverly, MA based biotech incuba-tor, and volunteers as a mentor with the MassBio MassCONNECT and the Boston University KINDLE startup accelerators. Previously, Dr. Frechette was a co-founder of MaxThera, Inc., a drug discovery company developing novel anti-infectives therapies. MaxThera’s assets were sold in early 2010 to Biota Holdings Lim-ited, a Melbourne Australia anti-infectives company. Prior to starting MaxThera, Dr. Frechette was Project Director at Paratek Pharmaceuticals, in Boston. At Paratek, he successfully led the team that discovered PTK0796 (currently in Phase III clinical trials), and directed the pre-clinical development program. Prior to Paratek, he was Associate Director of Chemistry at RiboGene, Inc, in Hayward, CA, where he built the chemistry department and managed two drug discovery programs in collaboration with a Japanese strate-gic partner (Dainippon Pharmaceuticals). He began his career as a medicinal chemist at the R.W. Johnson Pharmaceutical Research Institute (A Johnson and Johnson Company) in Raritan, NJ.
Dr. Frechette was a Post-Doctoral Fellow at Yale University, earned his PhD in Organic Chemistry from Wes-leyan University and his BA in Chemistry from College of the Holy Cross.
Johannes Fruehauf Founder and Executive Director, LabCentral
Johannes Fruehauf is the Founder of Cambridge BioLabs, a contract research facility servicing startup and virtual companies in Kendall Square, specializing in the development of startup ideas and validation of sci-entific concepts. The experience at CBL resulted in the joint development of the LabCentral concept, a new non-profit shared laboratory project supported by a major grant from the Commonwealth of Massachusetts and by Novartis Institute of Biomedical Research. LabCentral’s mission is to help accelerate the formation of new innovative biotech companies in Massachusetts. Johannes is a serial biotech entrepreneur, he is a co-founder at ViThera Pharmaceuticals, Deltix and Cequent Pharmaceuticals, and an advisor or Board member to numerous life sciences companies and non-profits. Dr. Fruehauf studied and practiced medicine in Ger-many and came to Boston for a research post-doc that resulted in the creation of Cequent Pharmaceuticals (now Marina Biotech NASDAQ: MRNA).
Carolyn GreenPresident and Director, Atreaon, Inc.
Ms. Green is President of Atreaon, Inc., a venture-backed biopharmaceutical company developing a family of novel engineered proteins for the treatment of autoimmune and inflammatory diseases. Atreaon recently completed a $20 million Series-A financing to support pre-clinical development. Previously, Ms. Green co-founded Logical Therapeutics, and as President she was instrumental in securing more than $45M in venture capital to move their anti-inflammatory pro-drugs through Phase 2b. Prior to coming to Boston, Ms. Green was the founding Director of a translational research and commercialization center at the University of Pitts-burgh School of Medicine, where she helped to commercialize promising discoveries emanating from more than $650 million in annual NIH research funding.
6th AnnualMassachusetts Life Sciences Innovation Day
20 Biographies
Julia GreensteinAssistant Vice President, Cure Therapies
Julia Greenstein is currently the Assistant Vice President for Cure Therapies. The Cure Therapies group at JDRF is responsible for the Beta cell replacement and regeneration and imaging portfolio and the Immune therapies portfolio at JDRF, the leading non-profit non-governmental funder of international research in type 1 diabetes. She has over 20 years of experience in the corporate biotechnology arena. She was the Chief Executive Officer and President of Immerge BioTherapeutics, Inc., a Novartis Pharma/BioTransplant joint venture, focused on the development of pig xenotransplantation for clinical practice. Prior to that, she has held the roles Chief Scientific Officer and Senior Vice President of Research at BioTransplant Incorporated and Vice President of Discovery Research at ImmuLogic Pharmaceutical Corp. Dr. Greenstein serves on the Board of Directors of the MGH Institute of Health Professions and the Mass BioEd Foundation and was on the Board of the Massachusetts Biotechnology Council and the Massachusetts Society for Medical Re-search. She received her Ph.D. in Microbiology from the University of Rochester Medical School based on work in the laboratory of Dr. Philippa Marrack. She did postdoctoral training at the University of Rochester Medical School and the Dana Farber Cancer Insititute of Harvard Medical School. Dr. Greenstein was an Assistant Professor at Harvard Medical School and the Dana Farber Cancer Institute.
Melissa Hunter-EnsorPartner, Saul Ewing LLP
Drawing on a strong scientific background that includes a post-doctoral fellowship with a Nobel laureate, Melissa Hunter-Ensor, Ph.D. is a patent attorney who designs and manages IP portfolios to complement the business objectives of her clients.
Melissa focuses her practice on the strategic development of patent portfolios in the fields of biochemistry, molecular and cell biology, immunology, biochemical and molecular diagnostics, pharmaceuticals, microbiol-ogy, molecular genetics, pharmacogenomics, recombinant technologies, enzyme replacement therapy, gene therapy, bioinformatics, drug discovery, medical devices and chemistry. Her clients range from start-ups to universities to global pharmaceutical companies.
Melissa also assists venture capital firms and other investors in assessing IP risks of target investments and conducts patent and licensing due diligence for life sciences transactions.
Melissa’s education includes a B.A. in chemistry at Smith College, as well as a Ph.D. in neuroscience at the University of Pennsylvania. Her thesis research resulted in a first author paper in Cell. During her post-doc-toral fellowship at the Massachusetts Institute of Technology laboratory of Nobel laureate H. Robert Horvitz, she was awarded a Jane Coffin Child fellowship.
Melissa is admitted to practice before the U.S. Supreme Court, the Federal Circuit of the U.S. Court of Ap-peals and the U.S. District Court in Massachusetts.
Frederick “Rick” JonesSerial Entrepreneur
Dr. Frederick Jones has had a wide-ranging career as a leader in healthcare and biopharma. Most recently Rick has founded two university spin-out companies - Spordiff, which is developing small molecule to prevent
June 5, 2013Harvard Club of Boston
Biographies 21
C. difficile infection and Roundhouse, which is developing small molecules and antibodies that target the isomerase Pin1 and its substrates for cancer and Alzheimer’s. Previously, Rick was CEO of Anchor Thera-peutics, a venture-backed company developing a platform of lipidated peptides targeting intractable GPCR targets. Before that Rick held increasingly responsible positions as a general manager, business develop-ment professional and medical affairs officer with Devgen, BioRexis and Wyeth Pharmaceuticals. Early in his career, Dr. Jones practiced internal medicine, most recently as Assistant Professor at the University of Pennsylvania health system.
Scott KennedyVP of Translational Medicine, Global Head of Biomarker Development, Novartis Institutes for Biomedical Research
Dr. Scott Kennedy is Vice President of Translational Medicine-Global Head of Biomarker Development for Novartis Institutes for Biomedical Research. In this role he leads a global group of scientists who work in partnership with Novartis and external translational biologists, physicians and teams to develop stratified medicines, such that the right patients get the right dose of the right medicine at the right time. After com-pleting a post-doctoral fellowship at Yale University School of Medicine in the Department of Pathology in 1992, Scott joined Alexion Pharmaceuticals, a biotechnology start-up company focusing on treatments for transplant rejection and imflammatory diseases. He then moved to Pfizer Global Research and Development from 1994-2008 where he assumed increasing levels of responsibility, including Head of Biology Research, Vice President of Development in Drug Safety Research and Development, and Head of Pfizer’s External Research Network. Prior to joining NIBR in 2010, Scott served as Chief Scientific Officer for RainDance Technologies, a biotechnology start-up company focusing on microdroplet technology applications in next generation sequencing and single cell analysis. Scott recieved his B.S. in Biochemistry from Trinity College and Ph.D. in Immunology from the University of Connecticut Health Center.
Ankit Mahadevia is a principal in the life sciences group and focuses on novel drug discovery platforms, therapeutic products, and other medical technologies that meet a significant unmet clinical need.
Prior to joining Atlas in 2008, Ankit worked on product and business development with the founding team at Arcion Therapeutics. He has also held positions in business development both at Genentech and at Vanda Pharmaceuticals. Previously, he worked in the health care groups of McKinsey & Company and Monitor Group. Ankit began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor, and Pensions committees, the U.S. Government Accountability Office, and the Mexican Institute of Social Security (IMSS).
Ankit currently serves on the boards of Atlas companies Annovation Biopharma, RaNA Therapeutics, Luma-vita, and Fibrex Medical. He also works closely with Arteaus Therapeutics, JenaValve, and Nimbus Discov-ery and previously worked with Sirion Therapeutics (acquired by Alcon and Bausch & Lomb). Ankit is also actively involved in the Shire/Atlas Venture Alliance and the Atlas/Monsanto Seed Fund Alliance.
Ankit received an MD from the Johns Hopkins University School of Medicine and an MBA from the Wharton School of the University of Pennsylvania. He received a BA in economics and biology, with honors, from Northwestern University, where he graduated summa cum laude.
6th AnnualMassachusetts Life Sciences Innovation Day
22 Biographies
Ankit was appointed by the U.S. Secretary of Health and Human Services to the Advisory Council of the NIH Center for Advancing Translational Sciences. He also serves on board of the Johns Hopkins Alliance for Technology Transfer, through which he promotes translation of biomedical research by biotechnology companies.
Michael MaloneVice Chancellor for Research & Engagement, UMass AmherstRonnie & Eugene Isenberg Distinguished Professor of Engineering
Mike Malone is Vice Chancellor for Research & Engagement at the University of Massachusetts Amherst and the Ronnie & Eugene Isenberg Distinguished Professor of Engineering. He was educated in chemi-cal engineering at Penn State University and at UMass Amherst, where he joined the faculty in 1980. At UMass he has been Director of the Process Design and Control Center for nine years, Department Head of Chemical Engineering for six years, and then Dean of Engineering for five years until 2009 when he was appointed Vice Chancellor. He has been a Visiting Scientist in Central Science & Engineering at the DuPont Company and has done extensive consulting for industry in the US and internationally. He is the author of numerous technical articles, four books, and an inventor on two patents for catalytic distillation. He has won many awards for his research on process design and for his teaching. He currently teaches an interdisciplinary course on Innovation & Entrepreneurship for science, engineering and management students and conducts research on reactive distillation for advanced biofuels production. He founded and continues to direct the UMass Innovation Challenge, a campus-wide business plan competition focused on science and engineering teams. He has served for more than four years on the Board of Directors of the National Collegiate Inventors and Innovators Alliance. In his role as Vice Chancellor, he is the Chief Research Officer for the campus and oversees research administration, including Commerical Ventures and Intellectual Property and the “UMass Innovation Institute” which he conceived and established in 2011. UMII enables the University of Massachusetts Amherst to expand the impact of its research in new direc-tions, with new partners, and through creative approaches to collaboration. The vision for UMII is to impact regional and national economic growth by ensuring that knowledge and technology developed at UMass are rapidly and broadly disseminated to advance the nation’s social and economic interests.
Albine MartinCOO, Precision Biologics, Inc.
Dr. Albine Martin brings over 20 years of operating and product commercialization experience with startup and three public companies representing the biotechnology, diagnostics and life sciences sector. She has served as a sector expert and member with Active Angels, and New Dominion Angels where she led diligence and syndicated investments. She currently serves as COO, Precision Biologics, Inc., a clinical development oncology company with a companion diagnostic. Precision is advancing its first program for colorectal and pancreatic cancer following the acquisition of assets from Neogenix Oncology where Dr. Martin served as COO. As Vice President at Compugen (CGEN), she built the first revenue generating model and alliance management programs to advance both diagnostic and therapeutic candidates. Dur-ing her tenure at Life Technologies [LIFE] she was responsible for the global portfolio as Senior Business Director and managed Joint Ventures and expansion within the Asia-Pacific region. She has collaborated with FDA/CBER to develop compliance standards and commercialization strategies for ancillary products within the Cellular Therapy arena. She was also part of the team that led the BLA approval and commer-
June 5, 2013Harvard Club of Boston
Biographies 23
cialization of the HPV molecular diagnostic test commericalized by Digene Diagnostics. Dr. Martin served as member of the start up team at Digene Diagnostics and led the creation of the first revenue generating busi-ness. She is a member of the NSF commercial reviewer panels for SBIR 1/2 funding programs and serves on the advisory board for BioHealth Innovation, Rockville, Md. Dr. Martin holds a Ph.D. from the University of Maryland and served as a Staff Fellow at the National Institutes of Health and is a graduate of the Program on Leadership and Strategy in Pharmaceuticals and Biotech at the Harvard Business School.
Sanjeev MunshiDirector, External Research and Licensing, Merck Research Laboratories
Dr. Sanjeev Munshi is a Director in the External Research and Licensing organization of the Merck Research Laboratories. Sanjeev’s role is to identify partnering opportunities that fit with Merck’s strategic research and development goals across all therapeutic and technology areas. Sanjeev is primarily responsible for scout-ing and managing alliances in the Southern and Mid-Atlantic US. Sanjeev earned his Ph.D. in molecular biophysics (structural biology) from Indian Institute of Science, India and MBA from Villanova School of Busi-ness. Following a postdoctoral fellowship in structural virology at Purdue University, Sanjeev joined MRL at West Point, in 1995. After fifteen years of preclinical drug discovery research, Sanjeev moved into External Scientific Affairs in 2010. Sanjeev is based in Chapel Hill, North Carolina.
Auro NairGeneral Manager, JAX® Scientific Research Services
Since December 2011, Dr. Nair has served as General Manager of JAX® Scientific Research Services. In this role, Dr. Nair is responsible for all research services provided to both internal researchers at The Jackson Laboratory (TJL) and external researchers worldwide. In addition, Dr. Nair leads TJL’s product development and customer-facing functions. Dr. Nair joined TJL in January 2007 as Associate General Manager of JAX® Mice & Services. Prior to joining TJL, Dr. Nair served as Vice President, Worldwide Marketing and North American Sales with Caliper Life Sciences, Hopkinton, Massachusetts, where he had been responsible for commercialization of Caliper’s products and services. He had been with Caliper and its predecessor compa-ny, Zymark, since 1997. Previous to that Dr. Nair had managed Quality Compliance and Analytical Services at Glaxo’s FDA-approved site in Singapore, where he had been since 1990. Dr. Nair is a graduate in Chem-istry from the University of Science, Penang, Malaysia and holds a Ph.D. in Chemistry from the University of Oklahoma, Norman, OK. He has an Executive MBA from Suffolk University, Boston, Massachusetts. Dr. Nair, his wife, and their 2 children (13 and 10 years old) live in Bar Harbor, Maine.
Mark NamchukSenior Vice President of Research for North America, Vertex Pharmaceuticals
Dr. Namchuk received his BSc in Chemistry with Honors from the University of Alberta in 1988 and his Ph.D. in Bioorganic Chemistry from the University of British Columbia in 1993. Upon completion of his graduate work, Dr. Namchuk was an HFSP Post Doctoral Fellow at UCSF. In 1996 he accepted a position with Cub-ist Pharmaceuticals as the head of the Enzymology group. In 1998, he joined Vertex Pharmaceuticals and
6th AnnualMassachusetts Life Sciences Innovation Day
24 Biographies
has held a number of positions with the company. In 1999, he took on responsibility for the High Throughput Screening group. After leading drug discovery teams in infectious disease and oncology, he was promoted in 2002 to Worldwide Head of preclinical research for the Vertex/Novartis Kinase Program, and in 2003 took responsibility for all aspects of the alliance across R and D. In 2005, Dr. Namchuk was made Vice President of Research for Vertex’s Cambridge site. In 2011 he was promoted to his current position as senior Vice President of Research for North America. In this position he manages 350 scientists in 4 sites working in all areas of pharmaceutical research including Medicinal Chemistry, Structural Biology, Biochemistry, Cell Biol-ogy and Pharmacology and oversees projects in areas of Infectious Disease, Oncology, IMID, Neurology and Cystic Fibrosis.
Gerard O’ConnorPartner, Saul Ewing LLP
O’Connor is the first corporate attorney to join the ranks in the Boston office, expanding Saul Ewing LLP’s services offered there.
O’Connor has a wide-ranging business practice focused on mergers and acquisitions, corporate finance and intellectual property matters. He represents clients in a variety of industries, including clean energy technol-ogy, renewable energy, software and information technology, medical device and life sciences, manufactur-ing, venture capital and professional services.
His experience includes representing buyers and sellers of public and private companies and assisting entre-preneurs and early stage companies with formation, securities offerings, employment and intellectual prop-erty issues. He also counsels public companies and their directors and officers on securities law, Sarbanes-Oxley compliance and reporting obligations. In addition, O’Connor advises early stage energy technology companies and software companies in their formation and growth, including the negotiation and execution of angel and venture capital financings, strategic alliances and joint venture agreements.
O’Connor received his law degree from Northeastern University School of Law and his undergraduate de-gree from the University of Massachusetts, Amherst.
Joshua PhillipsManaging Partner, Catalyst Health Ventures
Joshua Phillips is the Managing Partner of Catalyst Health Ventures (CHV), an early stage healthcare and life science focused venture firm in the Boston area. Josh leads Catalyst’s investment activities in all areas. Josh represents CHV on the boards of Allegro Diagnostics Inc., Vortex Medical Inc., BioTrove Inc. (Chair-man), HepreGen Corp., and Castel Inc. (Chairman) and previously lead CHV’s investment in Novazyme Pharmaceuticals (acquired by Genzyme). CHV invests in companies developing technology applications in healthcare and life sciences, typically medical devices, molecular diagnostics, and tools and infrastructure for genomics and drug discovery. CHV is an active investor, often a lead or co-lead, that focuses on forging partnerships with entrepreneurs and co-investors to deliver superior returns.
Prior to joining CHV in 2000, Josh was a Manager at the Lucas Group, a strategy consulting firm where he focused on engagements in the pharmaceutical, medical device, and technology industries, often involving a transaction. Earlier, Josh founded and built a new business unit within privately held Russelectric, develop-ing and deploying digital turbine control systems for power generation and industrial applications. Josh be-gan his career with the Government Engine Business within Pratt & Whitney Aircraft, developing and testing the digital control system for the USAF F-22 fighter engine. Josh holds a B.E. in Electrical Engineering and Mathematics from Vanderbilt University and an MBA from Harvard Business School.
June 5, 2013Harvard Club of Boston
Biographies 25
Linda PlanoFounder, Plano & Simple
Linda founded Plano & Simple based on her experiences at the Massachusetts Technology Transfer Cen-ter (MTTC) where she was officially the Associate Director and unofficially both coach and “yenta” to liter-ally hundreds of entrepreneurs for the state of Massachusetts. These entrepreneurs went on to raise over $250M prior to her departure in 2009. Linda has since expanded her coaching to online and in-person work-shops to help early stage entrepreneurs succeed, including those that are located away from entrepreneur-ship centers such as Boston.
In addition to coaching, Linda helped to manage several major investor pitch events each year, including the Conference on Clean Energy and the Early Stage Life Sciences Conference, which featured in total about 200 entrepreneurs. She ran the Conference on Clean Energy, leading its growth from a one day event with a hundred people in attendance to the largest event of its kind in the region, spanning three days and anchor-ing Massachusetts’ Clean Energy Week.
Prior to becoming Associate Director at MTTC in 2005, Linda co-founded the Ignite Clean Energy Business Competition with other founding members of the Energy Special Interest Group at the MIT Enterprise Forum of Cambridge. She ran it on a volunteer basis for two years, helping dozens of entrepreneurs in the clean energy space to improve their business plans and raise funding.
Linda has held management positions up to Vice President, New Business Development in established companies (Kobe Steel Electronic Materials Center, Sarnoff Corporation, Micro Networks Corporation) and positions ranging from Research Scientist to CEO of startup companies. She received a PhD in Materials Science and Engineering from Stanford and a BS in Physics from MIT.
Her work in clean energy entrepreneurship led to awards from the Massachusetts Technology Leadership Council, the MIT Enterprise Forum of Cambridge and the Global MIT Enterprise Forum, as well as board seats on the Massachusetts Renewable Energy Trust, the New England Clean Energy Council and both the local and global MIT Enterprise Forums.
Kevin PojasekEntrepreneur-in-residence, Atlas Venture
Kevin Pojasek is an entrepreneur-in-residence at Atlas Venture where he’s creating and running early stage life science companies. Prior to joining Atlas in January, Dr. Pojasek was Vice President of Corporate De-velopment at Kala Pharmaceuticals, a venture capital-backed developer of novel ophthalmology therapies, where he was responsible for the company’s corporate strategy, financing, day-to-day operations, and busi-ness development activities. Dr. Pojasek joined Kala from Satori Pharmaceuticals where he oversaw the company’s development activities for the lead Alzheimer’s disease program. Prior to Satori, Dr. Pojasek co-founded and was the Executive Director of Development at Solace Pharmaceuticals where he oversaw the clinical development of the company’s lead compound, including the execution of a global Phase II neuropathic pain study. Dr. Pojasek also spent time at PureTech Ventures, an early stage venture capital firm, where he led the formation and management of several life science companies based on innovative technologies from diverse scientific fields. Dr. Pojasek received his PhD from the Biological Engineering Department at MIT and his BA from the Molecular, Cellular and Developmental Biology Department at the University of Colorado, Boulder.
6th AnnualMassachusetts Life Sciences Innovation Day
26 Biographies
Kiran ReddyAssociate Partner, Third Rock Ventures, LLC
Kiran Reddy is an Associate Partner at Third Rock Ventures and joined the firm in 2008. He supports and manages various portfolio companies in addition to focusing on new company formation and due diligence. Presently, he serves as interim Chief Business Officer for SAGE Therapeutics. Kiran was part of the team that launched Foundation Medicine, and he has served as a Board Observer for Alnara pharmaceuticals, Rhythm pharmaceuticals, and PanOptica pharmaceuticals. Prior to joining Third Rock Ventures, Kiran was a management consultant at the Lewin Group within the biotechnology and pharmaceutical practice, and advised clients on clinical development and commercial strategy. Kiran holds MD and MBA degrees from Georgetown University. He completed his internship in medicine and his neurology residency at Harvard/Massachusetts General Hospital and is a board certified neurologist. Kiran was previously a Howard Hughes science fellow, and has authored several peer-reviewed scientific papers in the fields of neuroimmunology and neurodegenerative diseases.
Scott Samuels Member, Mintz Levin
Scott Samuels focuses his practice on corporate and securities law matters, primarily for life sciences and technology companies. Scott represents founders, private and public companies, venture capital funds, an-gel investors, underwriters, and other parties in a broad range of transactions, including corporate forma-tions, financings and mergers and acquisitions. Scott regularly advises earlier stage companies on general corporate matters, including formation, stock option and equity plans, financing, confidentiality/invention as-signment agreements and employee/consultant matters, and has built a network of VC and angel investors through this portion of his practice. He received his BA from Cornell University and his JD from George Ma-son University, where he was editor-in-chief of the law review.
Aaron is a Co-Founder and Managing Director of Norwich Ventures, a specialized venture capital firm fo-cused on early-stage MedTech. Aaron currently serves on the Board of Directors for Daktari Diagnostics, Pelvalon, and Podimetrics. Previously, he served on the board of Intelligent Biosystems (acquired by Qiagen) and was actively involved in Rhythmia Medical (acquired by Boston Scientific). Prior to co-founding Norwich Ventures, Aaron began his career as a consultant at McKinsey & Company and DEKA R&D. Aaron serves as a board member of MedTech IGNITE, a MassMEDIC initiative for early-stage medical device companies. Aaron earned an MBA from Harvard Business School and A.B.’s in Chemistry and Economics from Dart-mouth College.
June 5, 2013Harvard Club of Boston
Biographies 27
Michael SchraderFounder, CEO, Vaxess Technologies
Michael Schrader is the Founding CEO of Vaxess Technologies, a company revolutionizing global health by creating heat-stable vaccines. Vaxess’s patented technology uses a silk-derived protein to stabilize vaccines so they can be stored and shipped around the world without refrigeration. Vaxess is partnering with vaccine manufacturers to apply this technology to their products, lowering costs and increasing global access. The company was the winner of the 2013 Harvard Business Plan Competition and the 2012 Harvard President’s Challenge for Social Entrepreneurship. The company’s technology has been featured in The Economist, INC Magazine, Fast Company, CNBC, and NPR. Prior to founding Vaxess, Michael spent time at Google, Toyota Motor Manufacturing, and Honda R&D, where he earned more than ten patents for innovative new designs. Michael received his B.S. in Mechanical Engineering from Purdue University and his M.B.A. from Harvard Business School.
Josh TolkoffAccelerator Program Executive, CIMITManaging Director, Ironwood Equity Fund
Josh works at CIMIT, Center for Integration of Medicine and Innovative Technology. In addition, he is a Man-aging Director of Ironwood Equity Fund. Josh founded and managed Seedling Enterprises, a successful medical device accelerator. Josh founded ACT Medical, which became a premier medical device contract developer and manufacturer. Josh was head of research and development for Medi-Tech, the founding divi-sion of Boston Scientific. He is a corporate Director of numerous for-profit growth companies, past chair of MassMedic and past chair of the advisory board of the Harvard-MIT program in Health Sciences and Tech-nology. He is the founding board chair of Interise, a non-profit helping small urban companies develop and execute new growth plans, now in over 35 US cities. Josh received a Bachelor degree with concentration in Engineering and Applied Physics from Harvard College and a Masters majoring in BioMechanics from MIT. Josh lives in Brookline, MA with his wife, Ann Connolly Tolkoff, co-founder of City on a Hill Charter School.
Robert ThompsonPresident and CEO, Amorphex Therapeutics LLC
Mr. Thompson is a founder of Amorphex Therapeutics, a company that has successfully developed sus-tained, non-invasive ophthalmic drug delivery technology. He has over 20 years of executive experience in medical device and OTC markets including several early stage companies. Through his consulting practice he also acted as the intermediary in the sale/divestiture of two separate ophthalmic product lines.
He was formerly a corporate officer of Bausch & Lomb and president of Polymer Technology Corporation. Mr. Thompson joined Polymer Technology in its early, venture capital financed stage prior to acquisition by Bausch & Lomb and held various senior marketing and operational positions as the company grew to be-come the world’s leading provider of gas permeable contact lens products.
Mr. Thompson is a graduate of Boston University’s School of Management and of Harvard Business School’s Program for Management Development.
6th AnnualMassachusetts Life Sciences Innovation Day
28 Biographies
Mike TravisPrincipal, Travis & Company
Mike Travis is Principal at Travis & Company, an executive search firm that specializes in recruiting for life sciences. For almost two decades, Mike has served clients by recruiting general management, board mem-bers and function heads for medical device, diagnostic, and biopharmaceutical companies. He also recruits board members in all industries. He’s worked with a broad range of clients, from early-stage startups to large public companies. Mike is active in MassMEDIC and is the co-chair of the Life Sciences Circle at the MIT Enterprise Forum. He frequently writes and speaks on topics related to building management teams and managing talent. Mike earned a BA from Haverford College and an MS from the University of Chicago.
Leslie WilliamsDirector, Founder, President and CEO, ImmusanT, Inc.
Ms Williams is Founder, President & CEO of ImmusanT . The company is developing a revolutionary thera-peutic vaccine and companion diagnostic technology for treatment of Celiac disease, with plans to extend the technology to other immune mediated diseases, beginning with T1D.
Williams has extensive industry experience in pharmaceuticals, device/equipment and venture capital. As Ventaira President/CEO she transformed the company into a significant player in the pulmonary-drug-deliv-ery market and managed its acquisition. With INO Therapeutics, Inc., she served as Director of Marketing and Sales, and played a role in the NDA submission for the novel drug INOmax. Responsible for the com-mercial aspects of INOmax’s U.S. market introduction, Williams also assisted with expansion of the INO-therapy platform into the European marketplace. (The company was acquired by Ikaria Holdings in 2007 for some $670 million.) She has pharmaceutical commercial experience at Merck and GSK and drug-delivery/monitoring experience at Datex-Ohmeda. As a Venture Partner she sourced/evaluated deals; assisted early-stage technology companies with strategy, management, business development and M&A.
She serves on the Boards of Hepregen Corporation, and The Capital Network; is on the Editorial Advisory Board of Life Science Leader; serves as a mentor in the Boston University Kindle Program and Propel Ca-reers. She holds a B.S. degree with honors in nursing from the University of Iowa and an MBA from Wash-ington University.
June 5, 2013Harvard Club of Boston
Planning Committee 29
MALSI Day Planning Committee
Chair
Abi Barrow, Massachusetts Technology Transfer Center
Content
Richard Anders, MA Medical AngelsAbi Barrow, Massachusetts Technology Transfer Center
Carl Berke, Partners HealthcareLauren Laidlaw, T1D Exchange
Mark Namchuk, Vertex Pharmaceuticals Aaron Sandoski, Norwich Ventures
Marketplace
Shelley Amster, ShelleyCO, LLC
Research & Startup Showcase and Logistics
Sergio Davila, Harvard Biotech ClubRicha Dixit, Harvard Biotech Club
Shyh-Chang Ng, Harvard Biotech ClubAshim Subedee, Harvard Biotech Club
Julia Goldberg, Massachusetts Technology Transfer Center
Reception
Lauren Laidlaw, T1D ExchangeDenise Aronson, Safety Partners, Inc.
Team
Michele Bernier, Massachusetts Technology Transfer Center Kevin O’Sullivan, MA Biotech Incubator
Gary Lavine, Waltham Consulting
30 Sponsors & Organizers
6th Annual Massachusetts Life Sciences Innovation Day
Sponsors & Organizers 31
June 5, 2013Harvard Club of Boston
Sponsors and OrganizersGold Sponsors....................................................................................................................................... 32
Massachusetts Life Sciences Center .......................................................................................................................32
Conference Supporters ..................................................................................................................... 35Lathrop & Gage LLP .....................................................................................................................................................35Mintz Levin Cohn Ferris Glovsky and Popeo PC .................................................................................................35Vertex Pharmaceuticals ..............................................................................................................................................35MassGlobal Partners .....................................................................................................................................................35
Organizers .............................................................................................................................................. 36Massachusetts Technology Transfer Center .........................................................................................................36Mass Medical Angels ...................................................................................................................................................37Harvard Biotechnology Club .....................................................................................................................................37MALSI .................................................................................................................................................................................38
In association with ............................................................................................................................. 39Boston Life Science Networking .............................................................................................................................39CIMIT ..................................................................................................................................................................................39Harvard Alumni Entrepreneurs ................................................................................................................................39Lemelson-MIT .................................................................................................................................................................39M2D2 ..................................................................................................................................................................................39MASS-AWIS .....................................................................................................................................................................39Massachusetts Biomedical Initiatives ....................................................................................................................39MassChallenge Inc. .......................................................................................................................................................39MassMedic .......................................................................................................................................................................39Massachusetts Technology Collaborative ...........................................................................................................39Massachusetts Technology Leadership Council .................................................................................................39NCIIA ..................................................................................................................................................................................39NEVCA ...............................................................................................................................................................................39North Shore InnoVentures ........................................................................................................................................39OPEN .................................................................................................................................................................................39Seeding Labs ...................................................................................................................................................................39The Bioscience Network .............................................................................................................................................39The Capital Network ....................................................................................................................................................39TiE ........................................................................................................................................................................................39WEST ..................................................................................................................................................................................39University of Massachusetts ......................................................................................................................................39
32 Sponsors & Organizers
6th Annual Massachusetts Life Sciences Innovation Day
Gold Sponsor
Sponsors & Organizers 33
June 5, 2013Harvard Club of Boston
Silver Sponsor
Silver Sponsor
300 Technology Square, Eighth FloorCambridge, MA 02139
(617) 674-5100www.MassBio.org
The Massachusetts Biotechnology Council is an association of more than 620 biotechnology companies, universities, academic institutions and other organizations dedicated to advancing cutting edge research. We are the leading advocate for the Bay State’s world premier life sciences cluster. We drive innovation by convening the biotechnology community. We work to educate policy makers and the general public on the life-changing work biotech companies do every day. Our eff orts help infl uence public policy and advance the economic interests of individual companies as well as the sector as a whole.
Networking & Professional DevelopmentWe bring members together to discuss relevant business and scientifi c issues and share their experiences through members-only Forums and networking events. These gatherings allow our members to discuss and share their experiences, ideas and advice about the numerous issues and challenges that life sciences companies face every day. MassBio, through MassBioEd, also off ers workforce development courses and training programs for those looking to learn more about specifi c disciplines within the industry.
Access to Capital & Fostering InnovationWith our Innovation Services arm, MassBio is focused on matching our member companies with the resources they need to move cutting-edge therapies from the bench to the bedside. Programs like our Pharma Days series provide a venue for leaders from burgeoning biotech companies to hear about the vision of larger biotech and pharmaceutical companies, venture fi rms, and non-dilutive funding sources, and to make connections that may become successful collaborations or strategic partnerships. MassCONNECT links new entrepreneurs with seasoned biotechnology professionals to provide industry expertise, evaluation, and guidance as a means to help commercialize new ideas.
Purchasing PowerBy aggregating the purchasing power of the member companies within MassBio, the Purchasing Consortium allows members to have a strong presence in the marketplace and benefi t from discounts and top notch customer service. Current Purchasing Consortium contracts allow MassBio members to access savings in key cost centers, including laboratory supplies, offi ce supplies & furniture, shipping, hazardous & biomedical waste removal, packaged and bulk gases, instrument maintenance, travel and mobile communications support.
Public Policy & AdvocacyBiotechnology is a complex, highly regulated industry. At MassBio, we work to educate policy makers and the public about the specifi c needs of our companies as they push the boundaries of science to improve our lives. As the state’s leading advocate for our life sciences supercluster, we fi ght for public policy initiatives and tax incentives in Massachusetts that will enable biotechnology companies to do their best work. At the same time, we maintain an active presence in Washington to help guide federal legislation.
Economic Development & Industry DataMassBio provides expert advice and guidance to help companies fi nd suitable locations and resources as they move to and grow in the Bay State. With initiatives like the BioReady® Communities Campaign, which rates a municipality’s zoning practices and infrastructure capacity for biotech development, we make Massachusetts a better place for your business. We also collect and disseminate current industry statistics, including employment and VC investment data.
MassBio Signature EventsWe bring together the various components of the life sciences supercluster through several compelling conferences and programs developed around the needs of our members. These events are opportunities for networking, educating and moving the industry forward. Annual events include the Policy Leadership Breakfast, the MassBio Annual Meeting and the MA CRO/CMO Symposium.
34 Sponsors & Organizers
6th Annual Massachusetts Life Sciences Innovation Day
Macroview.Microfocus.One
law firm.
The attorneys at Saul Ewing examine business, intellectualproperty and other legal issues
through different lenses, combining big-picture analysis
with scrutiny of the finer details.
Getting multiple perspectivesfrom the same law firm gives
our life sciences clients a singular advantage.
Saul Ewing is a proud sponsorof Massachusetts
Life Sciences Innovation Day 2013.
DELAWARE MARYLAND MASSACHUSETTS NEW JERSEY NEW YORK PENNSYLVANIA WASHINGTON, DC
GERARD P. O'CONNOR, PARTNER 131 Dartmouth Street Suite 501 Boston, MA 02116 617.912.0965 www.saul.com
The choice of a lawyer is an important decision and should not be based solely upon advertisements. For more information, contact Giulio DeConti at (857) 300-4000.
Lathrop & Gage is Proud to Support
MASSACHUSETTS LIFE SCIENCES
INNOVATION DAY
CALIFOrNIA | COLOrADO | ILLINOIS | KANSAS |
MASSACHUSETTS | MISSOUrI | NEW YOrK
(857) 300-4000 | LATHrOPGAGE.COM
Information contained herein may be considered attorney advertising. Prior results do not guarantee a similar outcome. 2987
Isn’t it time your law firm focused on what matters to you?
It’s time.
You need to execute a strategy that will build value and
sustain the health of your business. Our attorneys have the
experience, resources, and know-how to help you navigate
industry-specific challenges and obstacles to meet your
goals. Since the birth of the life sciences industry in the
1970s, we’ve helped individuals and companies with
their transactional, regulatory, and intellectual property
matters. Your success is our success.
www.mintz.com
36 Sponsors & Organizers
6th Annual Massachusetts Life Sciences Innovation Day
The Massachusetts Technology Transfer Center is funded by the Commonwealth of Massachusetts. Its goal is to support technology transfer activities from public and private research institutions to companies in Mas-sachusetts. To achieve this goal, the Center works with technology transfer offices at Massachusetts research institutions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth.
The Center supports the commercialization of research technologies through a variety of programs:
The Center provides mentoring to researchers who believe they have a technology that could serve as the basis of a new company. The process includes the development of a business presentation for an expert board of external reviewers.
Commercialization and Entrepreneurial Education seminars and workshops enable researchers to understand the process of commercializing technologies.
Expert technology reviews provide opportunities for Massachusetts research institutes to have external industry experts evaluate technologies and give advice regarding their commercial potential.
Technology Forums allow investors and potential corporate partners to meet with companies formed around technologies developed in Massachusetts research institutes.
6th Annual Massachusetts Life Sciences Innovation Day
We are motivated to leverage what is truly unique about MA
“If I stand in the middle of Mass Ave Bridge, and walk 1 mile in either direction, I have everything I need to start a billion dollar life sciences company”
The Massachusetts Life Sciences Start-up Initiative (MALSI) is a collaborative group of public and private entities that work with emerging biotech and biomed companies. The prime aim of MALSI is to ensure that every life sciences entrepreneur or researcher who has a commercializable idea has easy and rapid access to the vast network of organizations and individuals who can help them realize their dreams. The Massachusetts Technology Transfer Center, Mass MEDIC, TiE Boston, and MassBio have partnered to present the Massachusetts Life Sciences Innovation Day.
The Organizing Committee thanks our Non-Profit Affiliates:
40 Sponsors & Organizers
6th Annual Massachusetts Life Sciences Innovation Day
June 5, 2013Harvard Club of Boston
Poster Presenters 41
Poster PresentersBeth Israel Deaconess Medical Center ......................................................................................... 43
David Friedman, Instructor in Medicine
Beth Israel Deaconess Medical Center ......................................................................................... 43Annalisa Di Ruscio, Research Fellow
Boston University ................................................................................................................................ 43Steven White, Business Development Analyst
Boston University ................................................................................................................................ 43Vishwajeet Puri, Professor of Medicine
Broad Institute of MIT and Harvard ............................................................................................... 43Andrea De Souza, Director Informatics, Finance, Data Analysis, Therapeutics Platform
CuriRx, Inc ............................................................................................................................................... 44Indu Javeri, CEO
Flow Forward Medical, LLC .............................................................................................................. 44Howard Loree, VP, Research & Development
Harvard Medical School .................................................................................................................... 44David Strochlic, Research Assistant
Harvard Medical School .................................................................................................................... 44John Collier, Professor
Harvard Medical School .................................................................................................................... 44Daria Prilutsky, Associate, Biomedical informatics
Harvard Medical School .................................................................................................................... 45Sandeep Robert Datta, Assistant Professor
Harvard University .............................................................................................................................. 45JoelKralj, Postoctoral Researcher
LambdaVision, Inc ............................................................................................................................... 45Nicole Wagner, CEO
Massachusetts Institute of Technology ....................................................................................... 45Jung-Jae Lee, Postdoctoral Associate
6th Annual Massachusetts Life Sciences Innovation Day
42 Poster Presenters
Massachusetts Institute of Technology ....................................................................................... 46Nigel Reuel, PhD Candidate & NSF Fellow
Northeastern University .................................................................................................................... 46Amir Farjadian, PhD Candidate
The Forsyth Institute ........................................................................................................................... 46Sean Cotton, Senior Research Assistant/ & Technology Development Manager
TriBiotica LLC ......................................................................................................................................... 46Estelle Newton, Director of Cell Biology
Tufts University ..................................................................................................................................... 46Michele Jacob, Professor of Neuroscience, School of Medicine
Tufts University School of Medicine ............................................................................................. 47Mercio Perrin, Professor of Pathology
Tufts University School of Medicine ............................................................................................. 47Rajendra Kumar-Singh, Associate Professor of Ophthalmology
Tufts University ..................................................................................................................................... 47Sergio Fantini, Professor, Department of Biomedical Engineering
Tufts University ..................................................................................................................................... 47Chris Pirie, Assistant Professor of Clinical Sciences, Tufts School of Veterinary Medicine
Tufts University ..................................................................................................................................... 47Jennifer Nwankwo, PhD Candidate
Tufts University ..................................................................................................................................... 48Jonathan Kluge, Postoctoral Researcher
University of Massachusetts Dartmouth ..................................................................................... 48Yuegang Zuo, Professor
University of Massachusetts Lowell .............................................................................................. 48Nan Wu, Dr., Electrical and Computer Engineering Department
University of Massachusetts Medical School............................................................................. 48Artem Kutikov, PhD Candidate, Depts. of Orthopedics & Cell Biology
Wyss Institute & Harvard University .............................................................................................. 48Joo Kang, Technology Development Fellow
June 5, 2013Harvard Club of Boston
43
Beth Israel Deaconess Medical CenterPresented by: David Friedman, Instructor in [email protected] Title: APOL1: A new target for treating and preventing kidney disease
Beth Israel Deaconess Medical CenterPresented by: Annalisa Di Ruscio, Research [email protected] Poster Title: RNA mediated gene-specific DNA demethylation
Boston UniversityPresented by: Steven White, Business Development [email protected] Poster Title: iPSC-derived erythroid cells
Boston UniversityPresented by:Vishwajeet Puri, Professor of Medicine [email protected] Poster Title: Lipid Production in Vegetative Tissues
Broad Institute of MIT and HarvardPresented by: Andrea De Souza, Director Informatics, Finance, Data Analysis, Therapeutics [email protected] Poster Title: BioAssay Research DataBase (BARD) – A Transformative Technology for Knowl-edge Sharing
6th Annual Massachusetts Life Sciences Innovation Day
44 Poster Presenters
CuriRx, IncPresented by: Indu Javeri, [email protected] Title: Novel nanoparticle liposome technology to deliver hydrophobic drugs with better safety, efficacy and PK profiles
Flow Forward Medical, LLCPresented by: Howard Loree, VP, Research & [email protected] Poster Title: Rotary Blood Pump System to Enhance Arteriovenous Fistula Eligibility
Harvard Medical SchoolPresented by: David Strochlic, Research [email protected] Poster Title: Molecular and Genetic Analysis of the Vagus Nerve
Harvard Medical SchoolPresented by: John Collier, [email protected] Poster Title: A novel anti-cancer ADC-like platform: Harnessing the Anthrax Toxin Power to Effectively Kill Tumor Cells
Harvard Medical SchoolPresented by:Daria Prilutsky, Associate, Biomedical [email protected] Poster Title: A Map of Human Normal and Disease Cell Signatures to Monitor and Drive Dif-ferentiation of Induced Pluripotent Stem Cell (iPSCs) for drug discovery and personalized therapeutics
June 5, 2013Harvard Club of Boston
45
Harvard Medical SchoolPresented by: Sandeep Robert Datta, Assistant [email protected] Poster Title: Comprehensive Behavioral Analysis for Drug Discovery
Harvard UniversityPresented by: JoelKralj, Postoctoral [email protected] Poster Title: Optogenetic tools for cardiac toxicity testing and drug discovery
Harvard University & Brigham & Women’s HospitalPresented by: David Raiser, Ph.D [email protected] Poster Title: PANDAA Pathogen and Drug Resistance Detection: Cutting Costs, Increasing Access, Improving Care
LambdaVision, IncPresented by: Nicole Wagner, [email protected] Poster Title: Development of a Protein-Based, Ion-Mediated Retinal Implant
Massachusetts Institute of TechnologyPresented by: Jung-Jae Lee, Postdoctoral [email protected] Poster Title: Synthetic ligand-coated magnetic nanoparticles for microfluidic bacterial separation from blood
6th Annual Massachusetts Life Sciences Innovation Day
46 Poster Presenters
Massachusetts Institute of TechnologyPresented by: Nigel Reuel, PhD Candidate & NSF [email protected] Poster Title: Dulce Detector™ - Nanosensor Array for On-line Analytics of Antibody Qual-ity and Glycosylation in Biomanufacturing
Northeastern UniversityPresented by: Amir Farjadian, PhD [email protected] Poster Title: vi-RABT: Virtually-interfaced Robotic Ankle and Balance Trainer
Roundhouse TherapeuticsPresented by: Frederick Jones, [email protected] Poster Title: PIN1 Modulators for Cancer: Roundhouse Therapeutics
The Forsyth InstitutePresented by: Sean Cotton, Senior Research Assistant/ & Technology Development [email protected] Poster Title: Novel Method of Stimulating the Body to Make Its Own Antimicrobials
TriBiotica LLCPresented by: Estelle Newton, Director of Cell Biology [email protected] Poster Title: Targeted Tumor Therapy: Turning the Genome on Its Head
Tufts UniversityPresented by: Michele Jacob, Professor of Neuroscience, School of Medicine [email protected] Poster Title: Autism, Learning Disabilities and Infantile Spasms Model
June 5, 2013Harvard Club of Boston
47
Tufts University School of MedicinePresented by: Mercio Perrin, Professor of [email protected] Poster Title: New Therapeutic Opportunity in PDNF as Cardioprotection Agonists
Tufts University School of MedicinePresented by: Rajendra Kumar-Singh, Associate Professor of [email protected] Poster Title: Peptide for Ocular Delivery (POD)-A Platform for Improving the Delivery of Pharmaceuticals to the Eye
Tufts UniversityPresented by: Sergio Fantini, Professor, Department of Biomedical [email protected] Poster Title: Coherent Hemodynamics Spectroscopy (CHS): A novel tool for the assess-ment of cerebrovascular integrity and functional neuroimaging
Tufts UniversityPresented by: Chris Pirie, Assistant Professor of Clinical Sciences, Tufts School of Veterinary [email protected] Poster Title: Adaptor for Standard Fundus and Fluorescein Angiography
Tufts UniversityPresented by: Jennifer Nwankwo, PhD [email protected] Poster Title: Pharmacological and Genetic Inhibition of Calpain-1 as a Novel Treatment for Sickle Cell Disease
6th Annual Massachusetts Life Sciences Innovation Day
48 Poster Presenters
Tufts UniversityPresented by: Jonathan Kluge, Postoctoral [email protected] Poster Title: Biospecimen Stabilization Using Silk Fibroin for Diagnostics
University of Massachusetts DartmouthPresented by: Yuegang Zuo, [email protected] Poster Title: Enzymatic, Photometric and Hydrophilic Interaction HPLC Methods for the Determination of Uric Acid and Creatinine in Human Biofluid and Disease Diognosis
University of Massachusetts LowellPresented by: Nan Wu, Dr., Electrical and Computer Engineering [email protected] Poster Title: High Frequency, All-Optical Ultrasound Transducer for Biomedical Applica-tions
University of Massachusetts Medical SchoolPresented by: Artem Kutikov, PhD Candidate, Depts. of Orthopedics & Cell [email protected] Poster Title: A biodegradable synthetic polymer/hydroxyapatite composite with im-proved handling characteristics and bioactivity for skeletal tissue engineering applica-tions
Wyss Institute & Harvard UniversityPresented by: Joo Kang, Technology Development [email protected] Poster Title: A Blood Cleansing BioSpleen Device for Sepsis Therapy
June 5, 2013Harvard Club of Boston
Innovator's Marketplace Exhibitors 49
Innovators’ Marketplace ExhibitorsLife Science Products and Services
